연구 및 보고서

Satellos Bioscience observed a drug activity signal for its oral AAK1‑targeting candidate SAT‑3247 in a Phase 1a/b trial of four adult Duchenne muscular dystrophy patients.

The 2026 Gwangju Pharmacist Academic Conference will feature an ‘AX Zone’ where participants can experience AI‑driven pharmacy automation, including compounding, inventory, counseling, and management.

The Korean BioBridge 2026 forum announced a new collaborative ecosystem linking technology, capital, regulation, market and innovators to boost advanced bio‑technology commercialization.

Xiaflex, the injectable enzyme already approved for Dupuytren's contracture and Peyronie's disease, achieved the primary endpoint in a phase 3 study of 436 plantar fibromatosis patients, opening a potential third indication.

Hanmi Pharm is developing Belvarafenib, the first oral targeted therapy for NRAS‑mutant melanoma, now in Phase 2 with a goal of conditional approval by 2028.

A joint Irish study shows dietary yeast β‑glucan can restore obesity‑impaired anti‑cancer immunity and sustain improvements after weight loss by reprogramming bone‑marrow immune cells.

NCIA presented autophagy‑focused brain health research and unveiled the pharmacy‑only supplement NeuroAP at a Daegu pharmacist fair, with KAIST professor Park Ok‑nam discussing autophagy’s role in neurodegeneration.

Dioni Healthcare presented its NQO1‑targeted NAD+/ATP dual‑promotion and senolytic‑based health functional foods at the 2026 Daegu Pharmacy Farm Fair, attracting pharmacist interest.

A study of 2,474 Korean COPD patients found that coexisting cardiovascular disease raises the risk of severe exacerbations and increases medical expenses, prompting calls for integrated care.

Samsung Bioepis and Proteina signed a license option agreement to advance AI‑driven antibody drug discovery from candidate identification to commercialization, building on a government AI project.

Novartis Korea presented up to 6‑year follow‑up results and real‑world data for its PNH therapy iptacopan (PAVALTA) at the EHA 2026 meeting in Milan.

Jongkundang has established NURATEON, a dedicated R&D subsidiary offering full‑cycle drug development services, from new formulations to DDS research.